bedrolite

Bedrolite is a standardized pharmaceutical-grade medicinal cannabis product derived from the cultivar Cannabis sativa L. 'Rensina'. It is characterized as a **CBD-rich, THC-low cannabis flower and oil**, containing typically less than 1% tetrahydrocannabinol (THC) and about 8–9% cannabidiol (CBD). Due to its extremely low THC content, Bedrolite does not possess intoxicating or psychoactive properties. It is primarily used as an adjunct treatment for **treatment-resistant epilepsy**, including conditions such as Dravet syndrome and Lennox-Gastaut syndrome, especially in pediatric populations. Bedrolite is supplied in **cut flos (ground dried flower) and oil formulations**. The product’s mechanism of action is attributed to the modulation of the endocannabinoid system by CBD, which is thought to decrease seizure frequency and severity, though the precise molecular targets are not fully elucidated. Bedrolite is developed by Bedrocan and manufactured by both Bedrocan (Netherlands) and Target Healthcare (UK). Clinical trials and observational reports suggest significant benefit for certain cases of refractory epilepsy, though robust randomized clinical trial data are limited[3][5][6][2].

Brand names

Bedrolite

Other names

Cannabis sativa L. 'Rensina'